62 results on '"Merino, L."'
Search Results
2. Effect of calcium on the aggregation behaviour of caseinates
Catalog
Books, media, physical & digital resources
3. Determination, validation and standardization of a CMV DNA cut-off value in plasma for preemptive treatment of CMV infection in solid organ transplant recipients at lower risk for CMV infection
4. Decentralized Delayed-State Information Filter (DDSIF): A new approach for cooperative decentralized tracking
5. Biomarkers in a peat deposit in Northern Spain (Huelga de Bayas, Asturias) as proxy for climate variation
6. A probabilistic framework for entire WSN localization using a mobile robot
7. Computer vision techniques for forest fire perception
8. Reconstructing the history of beech ( Fagus sylvatica L.) in the north-western Iberian Range (Spain): From Late-Glacial refugia to the Holocene anthropic-induced forests
9. Traditional organic additives improve lime mortars: new old materials for restoration and building natural stone fabrics
10. Desarrollo de un protocolo de monitorización de fuga en perfusión de miembro aislado con gammacámara portátil.
11. Periodic urban models for optimization of passive solar irradiation.
12. Oxidative stability of iron fortified goat and cow milk and their peptide isolates.
13. Assessing the iron chelation capacity of goat casein digest isolates.
14. P.6.f.003 Identification of food craving biomarkers and potential drug targets in obesity: clusterin and serum amyloid p-component
15. 1770P Genomic correlates of clinical outcomes in patients with metastatic uveal melanoma (mUM) treated with tebentafusp (tebe).
16. Steady shear flow behavior of gum extracted from Ocimum basilicum L. seed: Effect of concentration and temperature
17. 2000 years of pastoralism and fire shaping high-altitude vegetation of Sierra de Gredos in central Spain
18. Starch–fenugreek (Trigonella foenum-graecum L.) polysaccharide interactions in pure and soup systems
19. (As,Sb)In/GaInSb quantum well for infrared detection enhancement
20. 331P Impact of ribociclib (RIB) dose reduction on overall survival (OS) in patients (pts) with HR+/HER2− advanced breast cancer (ABC) in MONALEESA (ML) -3 and -7.
21. Survival and germination of Mediterranean grassland species after simulated sheep ingestion: ecological correlates with seed traits
22. P126 - Implementation of a day care unit for inflammatory bowel disease: patients' satisfaction
23. 1080MO Sitravatinib plus tislelizumab for metastatic uveal melanoma with liver metastasis: The open-label, multicenter, phase II GEM-2101 trial.
24. Multimodal prehabilitation: a promising strategy in patients listed for heart transplantation.
25. Overall survival from tebentafusp versus nivolumab plus ipilimumab in first-line metastatic uveal melanoma: a propensity score-weighted analysis.
26. Unmanned aerial vehicles as tools for forest-fire fighting.
27. Experimental results of automatic fire detection and monitoring with UAVs.
28. 1078MO Pembrolizumab (pembro) vs placebo as adjuvant therapy for high-risk stage II melanoma: Long-term follow-up, rechallenge, and crossover in KEYNOTE-716.
29. Randomized phase II study of fulvestrant plus palbociclib or placebo in endocrine-sensitive, hormone receptor-positive/HER2–advanced breast cancer: GEICAM/2014–12 (FLIPPER).
30. Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival.
31. LBA44 Lenvatinib (len) plus pembrolizumab (pembro) for advanced melanoma (MEL) that progressed on a PD-1 or PD-L1 inhibitor: Initial results of LEAP-004.
32. Access to innovative medicines for metastatic melanoma worldwide: Melanoma World Society and European Association of Dermato-oncology survey in 34 countries.
33. 813P Time to development of central nervous system (CNS) metastases (mets) with atezolizumab (A) or placebo (P) combined with vemurafenib (V) + cobimetinib (C): Updated results from the phase III IMspire150 study.
34. 42TiP A multicenter, randomized, double-blind phase III study of HBI-8000 combined with nivolumab versus placebo with nivolumab in patients with unresectable or metastatic melanoma not previously treated with PD-1 or PD-L1 inhibitors.
35. The effect of lactoferrin on physical changes in phospholipid stabilised emulsions during neonatal in vitro gastric digestion: Does synergism of pepsin and lipase promote lipolysis in protein-stabilised emulsions?
36. 823P A propensity score weighted comparison of tebentafusp or pembrolizumab versus combination ipilimumab and nivolumab in untreated metastatic uveal melanoma.
37. Factors influencing the dynamics of emulsion structure during neonatal gastric digestion in an in vitro model.
38. 43O Pertuzumab/trastuzumab in early stage HER2-positive breast cancer: 5-year and final analysis of the BERENICE trial.
39. 1076O Adjuvant nivolumab (NIVO) vs ipilimumab (IPI) in resected stage III/IV melanoma: 4-y recurrence-free and overall survival (OS) results from CheckMate 238.
40. 14P Evolution of cytotoxic and regulatory T cells in blood and in tissue after neoadjuvant treatment in breast carcinoma.
41. Corrigendum to 'Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival': [Annals of Oncology Volume 32, Issue 8, August 2021, Pages 1015-1024]
42. 94MO Quality of life (QoL) with fulvestrant (FUL)/palbociclib (PAL) versus FUL/placebo (PBO) in postmenopausal women with hormone receptor (HR)+/HER2- endocrine sensitive advanced breast cancer (ABC): Results from GEICAM/2014-12 (FLIPPER) study.
43. LBA19 GEICAM/2014-12 (FLIPPER) study: First analysis from a randomized phase II trial of fulvestrant (F)/palbociclib (P) versus (vs) F/placebo (PL) as first-line therapy in postmenopausal women with HR (hormone receptor)+/HER2– endocrine sensitive advanced breast cancer (ABC)
44. 1143P Nivolumab and ipilimumab (N+I) is active in patients (pts) with metastatic uveal melanoma (mUM) with extra-hepatic only involvement: Pooled analysis from 2 phase II trials.
45. 1137P Incidence and time course of adverse events (AEs) with atezolizumab (A) in combination with vemurafenib (V) and cobimetinib (C) in the phase III IMspire150 study.
46. PMU23 COST OF ILLNESS IN PATIENTS WITH PSORIASIS AND PSORIATIC ARTHRITIS DISEASE. COEPSO STUDY.
47. 59P Myeloid derived-suppressor cells in healthy women and in advanced breast cancer patients.
48. 88PRun-in-phase results from a multicenter phase II trial to evaluate pembrolizumab (P) and gemcitabine (Gem) in patients (pts) with HER2-negative advanced breast cancer (ABC): GEICAM/2015-04 PANGEA-Breast.
49. 346PRibociclib (RIB) + fulvestrant (FUL) in hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC): MONALEESA-3 biomarker analyses.
50. 331PRibociclib (RIB) + fulvestrant (FUL) for advanced breast cancer (ABC): Progression-free survival (PFS) subgroup and tumor response analyses from MONALEESA-3.
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.